| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,006 | -751 |
| Share-based payment in exchange for services | 244 | 205 |
| Other current assets | -4 | 2 |
| Related parties | 527 | 336 |
| Account payables and accrued expenses | -25 | -27 |
| Depreciation | - | 0 |
| Net cash used in operating activities | -256 | -239 |
| Issuance of common stock and warrants | 240 | 240 |
| Advance payment on account of shares | - | 0 |
| Net cash provided by financing activities | 240 | 240 |
| Change in cash and cash equivalents | -16 | 1 |
| Cash and cash equivalents at beginning of period | 19 | - |
| Cash and cash equivalents at end of period | 3 | - |
Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. (RAPH)